Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bydureon Goes Back To The QTc Drawing Board

This article was originally published in The Pink Sheet Daily

Executive Summary

Amylin considers options for new study assessing cardiac safety, estimates resubmission timeline by year-end 2011.
Advertisement

Related Content

No Big Surprises From Lilly: Management Sticks To Its Guns On Strategy
No Big Surprises From Lilly: Management Sticks To Its Guns On Strategy
Two's a Crowd: Versartis Raises $21 Million Series B, Cleaves Off Diabetes Asset to Form Diartis Pharma
Two's a Crowd: Versartis Raises $21 Million Series B, Cleaves Off Diabetes Asset to Form Diartis Pharma
Novo Nordisk Toughens Long-Term Financial Targets As 2010 Sales Grew By 13%, Profits By 16%
Victoza Sales Lift Novo Nordisk 2010 Forecasts
On Q3 Earnings Call, Lilly Vows To Stay Its Current Course Despite Late-Stage Pipeline Setbacks
Amylin Hit Hardest By Bydureon Setback
FDA's "Complete Response" Letter For Byetta LAR Isn't Too Onerous, Amylin Says
FDA's "Complete Response" Letter For Byetta LAR Isn't Too Onerous, Amylin Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS071332

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel